Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;26(9):e26172.
doi: 10.1002/jia2.26172.

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy

Jienchi Dorward  1   2 , Richard Lessells  2   3 , Katya Govender  4 , Pravi Moodley  5 , Natasha Samsunder  2 , Yukteshwar Sookrajh  6 , Phil Turner  1 , Christopher C Butler  1 , Gail Hayward  1 , Monica Gandhi  7 , Paul K Drain  8   9   10 , Nigel Garrett  2   11
Affiliations

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy

Jienchi Dorward et al. J Int AIDS Soc. 2023 Sep.

Abstract

Introduction: Novel point-of-care assays which measure urine tenofovir (TFV) concentrations may have a role in improving adherence monitoring for people living with HIV (PLHIV) receiving antiretroviral therapy (ART). However, further studies of their diagnostic accuracy, and whether results are associated with viraemia and drug resistance, are needed to guide their use, particularly in the context of the global dolutegravir rollout.

Methods: We conducted a cross-sectional evaluation among PLHIV receiving first-line ART containing tenofovir disoproxil fumarate at enrolment into a randomized trial in two South African public sector clinics. We calculated the diagnostic accuracy of the Abbott point-of-care immunoassay to detect urine TFV compared to liquid chromatography-tandem mass spectrometry (LC-MS/MS). We evaluated the association between point-of-care urine TFV results and self-reported adherence, viraemia ≥1000 copies/ml and HIV drug resistance, among people receiving either efavirenz or dolutegravir-based ART.

Results: Between August 2020 and March 2022, we enrolled 124 participants. The median age was 39 (IQR 34-45) years, 55% were women, 74 (59.7%) were receiving efavirenz and 50 (40.3%) dolutegravir. The sensitivity and specificity of the immunoassay to detect urine TFV ≥1500 ng/ml compared to LC-MS/MS were 96.1% (95% CI 90.0-98.8) and 95.2% (75.3-100.0), respectively. Urine TFV results were associated with short (p<0.001) and medium-term (p = 0.036) self-reported adherence. Overall, 44/124 (35.5%) had viraemia, which was associated with undetectable TFV in those receiving efavirenz (OR 6.01, 1.27-39.0, p = 0.014) and dolutegravir (OR 25.7, 4.20-294.8, p<0.001). However, in those with viraemia while receiving efavirenz, 8/27 (29.6%) had undetectable urine TFV, compared to 11/17 (64.7%) of those receiving dolutegravir. Drug resistance was detected in 23/27 (85.2%) of those receiving efavirenz and only 1/16 (6.3%) of those receiving dolutegravir. There was no association between urine TFV results and drug resistance.

Conclusions: Among PLHIV receiving ART, a rapid urine TFV immunoassay can be used to accurately monitor urine TFV levels compared to the gold standard of LC-MS/MS. Undetectable point-of-care urine TFV results were associated with viraemia, particularly among people receiving dolutegravir.

Trial registration: Pan-African Clinical Trials Registry: PACTR202001785886049.

Keywords: HIV; adherence; point-of-care; tenofovir; urine assay; viral failure.

PubMed Disclaimer

Conflict of interest statement

Abbott provided the urine TFV assays at no cost. The authors have no other competing interests to declare.

Figures

Figure 1
Figure 1
Flow diagram of POwER study participants. Abbreviations: EAC, enhanced adherence counselling; HIVDR, HIV drug resistance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Murphy RA, Court R, Maartens G, Sunpath H. Second‐line antiretroviral therapy in sub‐Saharan Africa: it's time to mind the gaps. AIDS Res Hum Retroviruses. 2017;33(12):1181–1184. - PMC - PubMed
    1. Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low‐income and middle‐income countries. Lancet HIV. 2018;5(10):e588–596. - PubMed
    1. World Health Organization . Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2021. - PubMed
    1. Clinton Health Access Initiative . 2021 HIV market report: the state of the HIV market in low‐ and middle‐income countries. Boston, MA: Clinto Health Access Initiative; 2021.
    1. Seifert SM, Chen X, Meditz AL, Castillo‐Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32(10–11):981–991. - PMC - PubMed

Publication types